Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17068753 | 0.88 | MAPT (0.78) | MAPTTHRBLMNASMN1; SMN2NPC1 | |
| SCHEMBL17068794 | 0.87 | MAPT (0.77) | MAPTTHRBLMNASMN1; SMN2NPC1 | |
| SCHEMBL17068793 | 0.85 | MAPT (0.74) | MAPTTHRBLMNASMN1; SMN2NPC1 | |
| SCHEMBL17068790 | 0.85 | MAPT (0.74) | MAPTTHRBLMNASMN1; SMN2NPC1 | |
| SCHEMBL17068757 | 0.85 | MAPT (0.74) | MAPTTHRBLMNASMN1; SMN2NPC1 | |
| SCHEMBL17068799 | 0.84 | MAPT (0.73) | MAPTTHRBLMNASMN1; SMN2NPC1 | |
| SCHEMBL17068795 | 0.84 | MAPT (0.73) | MAPTTHRBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL17068756 | 0.82 | MAPT (0.70) | MAPTTHRBLMNASMN1; SMN2NPC1 | |
| SCHEMBL17068800 | 0.81 | MAPT (0.68) | MAPTTHRBLMNASMN1; SMN2NPC1 | |
| SCHEMBL17068797 | 0.79 | TP53 (0.68) | MAPTTHRBLMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150250769-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-09-10 | — | — | US | disclosed |
| US-20150250769-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250769-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | RHOA, ARHGEF1, ARHGEF2 | MAPT 2418/4885THRB 1319/4885LMNA 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.